Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 3/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | PKLR | P30613 | 1/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.42 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25502398 | 0.84 | CYP46A1 (0.55) | CYP46A1LMNAGAAPKLRGRIN2B | |
| SCHEMBL20147400 | 0.84 | CYP46A1 (0.50) | CYP46A1LMNAGAAPKLRGRIN2B | |
| SCHEMBL16051233 | 0.84 | CYP46A1 (0.50) | CYP46A1LMNAGAAPKLRGRIN2B | |
| SCHEMBL27967306 | 0.82 | CYP46A1 (0.63) | CYP46A1LMNAGAAPKLRGRIN2B | |
| SCHEMBL14840378 | 0.82 | CYP46A1 (0.54) | CYP46A1LMNAGAAPKLRGRIN2B | |
| SCHEMBL20147914 | 0.81 | CYP46A1 (0.48) | CYP46A1LMNAGAAPKLRGRIN2B | |
| SCHEMBL20070181 | 0.81 | RET (0.41) | CYP46A1LMNAGAAHRH4CYP1A2 | |
| SCHEMBL21940865 | 0.81 | HRH4 (0.41) | CYP46A1LMNAGAAHRH4CYP1A2 | |
| SCHEMBL25698977 | 0.79 | HRH3 (0.41) | CYP46A1LMNAGAAHRH4CYP1A2 | |
| Hydrochloric Acid SCHEMBL7842060 | 0.78 | CCR1 (0.41) | CYP46A1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3571203-B1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ARRAY BIOPHARMA INC. | 2022-04-21 | — | — | US | disclosed |
| US-20190263811-A1 | CRYSTALLINE FORMS | ARRAY BIOPHARMA INC. | 2019-08-29 | — | — | US | disclosed |
| WO-2018136661-A1 | SUBSTITUTED PYRAZOLO[1,5-a]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-07-26 | — | — | WO | disclosed |
| WO-2018071454-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS | ANDREWS STEVEN W (US) | 2018-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220119396-A1 | SUBSTITUTED PYRAZOLO[1,5-A]PYRAZINE COMPOUNDS AS RET KINASE INHIBITORS | RET, BRAF, ROR1 | CYP46A1 3995/4885LMNA 2693/4885GAA 3356/4885 |
| US-20190263811-A1 | CRYSTALLINE FORMS | RET, ALK, ROR1 | CYP46A1 3708/4885LMNA 1646/4885GAA 2406/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.